News | December 01, 2024
Dr. Reddy's launches Toripalimab in India
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
